Comparative Pharmacology
Head-to-head clinical analysis: IBUPRIN versus RELAFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPRIN versus RELAFEN.
IBUPRIN vs RELAFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
200-800 mg orally every 6-8 hours as needed; maximum daily dose 3200 mg.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours; in elderly or patients with hepatic impairment, half-life may be prolonged to 6-8 hours.
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Renal excretion of conjugated metabolites (75-85%), with less than 10% excreted unchanged; biliary/fecal elimination accounts for less than 10%.
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)